Outcome of transfusion of K:11 erythrocytes in a patient with anti-K11 antibody

Vox Sanguinis

Volumn 74, Issue 3, 1998, Pages 205-208

  Kelley, Carolyn M ^a   Karwal, Mark W ^a   Schlueter, Annette J ^a   Olson, John D ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIBODY;

ADULT; ARTICLE; BLOOD GROUP KELL SYSTEM; CASE REPORT; ERYTHROCYTE LIFESPAN; ERYTHROCYTE TRANSFUSION; FEMALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANEMIA; BLOOD GROUP INCOMPATIBILITY; DUODENAL ULCER; ERYTHROCYTE AGING; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; ISOANTIBODIES; KELL BLOOD-GROUP SYSTEM; KIDNEY FAILURE, CHRONIC; PEPTIC ULCER PERFORATION; POSTOPERATIVE COMPLICATIONS; RENAL DIALYSIS;

EID: 0031972090     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030933     Document Type: Article

References (19)

1. Issit PD: Applied Blood Group Serology, ed 3. Miami, Montgomery Scientific Publications, 1985, pp 289-295.
2. Marsh WL, Redman CM: The Kell blood group system: A review. Transfusion 1990;30:158-167.
3. Guevin RM, Taliano V, Waldmann O: The Côté serum, an antibody defining a new variant in the Kell system (abstract). 24th Annu Meet Am Assoc Blood Banks, Chicago, Ill., 1971, p 100.
4. Guevin RM, Taliano V, Waldmann O: The Côté serum (Anti-K11), an antibody defining a new variant in the Kell system. Vox Sang 1976; 31(suppl 1):96-100.
5. 17 as alleles in the Kell blood group system. Vox Sang 1975;29:450-455.
6. Vengelen-Tyler V (ed): Technical Manual, ed12. Bethesda, American Association of Blood Banks, 1996.
7. Brucer M: To measure red cell survival. Vignettes Nucl Med 1971;56:1-11.
8. Bernier D, Langen J, Wells D: Nuclear Medicine Technology and Techniques. St. Louis, Mosby, 1981,pp407-410.
9. Nance SJ, Arndt P, Garratty G: Predicting the clinical significance of red cell alloantibodies using a monocyte monolayer assay. Transfusion 1987;27:449-352.
10. Garratty G: Predicting the clinical significance of alloantibodies and determining the in vivo survival of transfused red cells: in Judd WJ, Barnes A (eds): Clinical and Serological Aspects of Transfusion Reactions. Arlington, American Association of Blood Banks, 1982, pp 91-119.
11. Kohan AI, Reybaud JF, Salamone JA, Rey CE, Villaravid N, Papa S, Cyrulik Goldztein S, Calahonra R, Sanchez Avalos JC: Management of a severe transfusional problem in a patient with alloantibody to Kpb (K4). Vox Sang 1990;59: 216-217.
12. Barrasso C, Baldwin ML, Drew H, Ness PM: In vivo survival of K:18 red cells in a recipient with anti-K18. Transfusion 1983;23:258-259.
13. Sabo B, McCreary J, Stroup M, Smith DE, Weidner JG: Another Kell-refated antibody, anti-K19. Vox Sang 1979;36:97-102.
14. Marsh WL, DiNapoli J, Oyen R, Greenspan R, Hu A, Rincon F: Delayed hemolytic transfusion reaction caused by a second example of antiK 19. Transfusion 1979; 19:604-608.
15. Posey WC, Nelson HS, Branch B, Pearlman DS: The effects of acute corticosteroid therapy for asthma on serum immunoglobulin levels. J Allergy Clin Immunol 1978;62:340-348.
16. Settipane GA, Pudupakkam RK, McGowan JH: Corticosteroid effect on immunoglobulins. J Allergy Clin Immunol 1978;62:162-166.
17. Lahood N, Emerson SS, Kumar P, Sorensen RU: Antibody levels and response to pneumococcal vaccine in steroid-dependent asthma. Ann Allergy 1993;70:289-294.
18. Abramson N, Gelfand EW, Jandl JH, Rosen FS: The interaction between monocytes and red cells. Specificity for IgG subclasses and IgG fragments. J ExpMed 1970;132:1207-1215.
19. Dixon FJ, Maurer PH: Immunologic unresponsiveness induced by protein antigens. J Exp Med 1955;101:245-257.